Chinese Middle Class Shuns Western Drugs In Favor Of Traditional Medicine (China)
This article was originally published in PharmAsia News
Executive Summary
Western drug makers are finding China's middle class a tough sell even though Chinese in that group are fans of U.S. cars and Starbucks. They still confine their drug spending to an average $10 a year, compared with the $900 American average. The Chinese middle class is as large as the entire U.S. population, but drug makers who have invested more than $1 billion in China the past 15 years have had little success in cracking the Chinese preference for traditional local medicine based on ingredients in plants. China also prohibits direct-to-consumer advertising for prescription drugs. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.